NASDAQ · Medical - Devices

DexCom, Inc. (DXCM) Stock

$77.94 -0.49% NASDAQ: DXCM Healthcare

Valuation

MetricValue
Price$77.94
Market Cap$29.41B
P/E Ratio33.44
P/B Ratio12.68
P/S Ratio6.58
EPS (TTM)$2.09
52-Week High$92.59
52-Week Low$54.11
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE36.19%
ROA15.49%
ROCE27.80%
Gross Margin19.56%
Operating Margin19.56%
Net Margin20.12%
Debt/Equity0.53
Current Ratio1.88

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.4B$2.9B$3.6B$4.0B$4.7B
Operating Profit$266.0M$391.0M$598.0M$600.0M$912.0M
Net Profit$217.0M$341.0M$542.0M$576.0M$836.0M
EPS$0.51$0.80$1.30$1.42$2.09
Op Margin10.9%13.4%16.5%14.9%19.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$4.9B$5.4B$6.3B$6.5B$6.3B
Total Liabilities$2.9B$3.3B$4.2B$4.4B$3.6B
Cash$1.1B$642.0M$566.0M$606.0M$918.0M
Borrowings$2.2B$2.1B$2.6B$2.6B$1.4B

Latest News

DXCM Secures Health Canada Authorization for Dexcom G7 15 Day CGM Zacks · Jul 14, 2026 1 Mid-Cap Stock to Target This Week and 2 We Find Risky StockStory · Jul 14, 2026 Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights GlobeNewswire · Jul 14, 2026 DexCom's G7 Glucose Monitor Receives Health Canada Authorization for Adults With Diabetes MT Newswires · Jul 13, 2026 Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes Business Wire · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$443.0M$670.0M$749.0M$990.0M$1.4B
Investing Cash Flow$-605.0M$-886.0M$-744.0M$-566.0M$173.0M
Financing Cash Flow$-10.0M$-575.0M$-788.0M$-763.0M$-507.0M
Net Cash Flow$235.0M$-410.0M$-76.0M$40.0M$312.0M
Free Cash Flow$53.0M$305.0M$512.0M$631.0M$1.1B

Valuation & Return Ratios

MetricValue
PEG Ratio0.44
EV / EBITDA21.15
FCF Yield4.30%
Quick Ratio1.43
Interest Coverage75.94
Return 1Y10.20%
Return 3Y-9.31%
Return 5Y-38.20%

Ownership

Insiders Held0.27%
Institutions Held102.22%
Institutions Float Held102.50%
Institutional HolderSharesReport Date
Blackrock Inc.38,964,3712026-03-31
Vanguard Capital Management LLC25,020,9612026-03-31
Vanguard Portfolio Management LLC19,219,9532026-03-31
State Street Corporation17,934,8472026-03-31
BAILLIE GIFFORD & CO15,599,5252026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
603087.SSGan & Lee Pharmaceuticals. $67.00 -4.03% — — 0.00%
BBNXBeta Bionics, Inc. $19.16 -0.93% -11.29 $862.00M 0.00%
DRIODarioHealth Corp. $3.77 +10.56% 8.41 $36.94M 0.00%
GCTKGlucoTrack, Inc. $0.40 -32.67% -0.01 $321811 0.00%
MMEDMiniMed Group, Inc. $18.34 +0.27% -18.33 $5.16B 0.00%

About DexCom, Inc.

DexCom, Inc. is led by CEO Jacob Steven Leach, employs 10,200 people, headquartered in San Diego, US, publicly traded since 2005.

DexCom, Inc. (DXCM) stock trades at $77.94 with a market capitalization of $29.41B. The stock is valued at a price-to-earnings (P/E) ratio of 33.44, price-to-book of 12.68, price-to-sales of 6.58. Over the past 52 weeks the stock has ranged between $54.11 and $92.59, and currently trades 15.8% below its 52-week high.

On profitability, DexCom, Inc. generates a return on equity (ROE) of 36.19%, above the typical market range of roughly 12-15%, return on capital employed of 27.80%, an operating margin of 19.56%, a net profit margin of 20.12%.

In its most recent fiscal year, DexCom, Inc. reported annual revenue of $4.7B, net profit of $836.0M. Over the last 5 fiscal years, revenue grew at an average annual rate of 19.3%, and net profit grew at an average annual rate of 11.1%.

The balance sheet shows a debt-to-equity ratio of 0.53, a current ratio of 1.88, total assets of $6.3B, $918.0M in cash and equivalents.

DXCM has an average daily trading volume of 4,441,466 shares, a beta of 1.42 (historically more volatile than the overall market).

DexCom, Inc. by the numbers, 2016–2025

Between 2016 and 2025 DexCom, Inc. reported revenue of $573.0M rising to $4.7B, a change of +713.6% across 10 years. Compounded, revenue has grown 19.3% a year over five years, 17.0% over three, 15.6% over the last twelve months. Net profit rose to $836.0M.

Operating margin went from -11.2% in 2016 to 19.6% in 2025, a gain of 30.7 percentage points. The most recent net margin is 20.12%. On a trailing twelve-month basis to Jun '26, revenue is $5.0B and net profit $1.0B.

Borrowings rose from $7.0M to $1.4B, cash from operations was $1.4B in the latest year, positive in 10 of the last 10.

Return on equity has averaged 22.1% over five years, and was 30.4% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

DexCom, Inc. (DXCM) — frequently asked questions

What is DexCom, Inc. (DXCM) stock price today?

DexCom, Inc. (DXCM) is currently trading at $77.94, down 0.49% today.

What is DXCM P/E ratio?

DexCom, Inc.'s P/E ratio is 33.44. This is above the typical market average of roughly 18-22x. A high P/E often reflects higher expected earnings growth, a temporary dip in earnings, or both.

What is DXCM return on equity (ROE)?

DexCom, Inc.'s return on equity (ROE) is 36.19%. ROE measures net income relative to shareholders' equity. This is above the typical market range of roughly 12-15%.

What is DexCom, Inc.'s market cap?

DexCom, Inc. has a market capitalization of $29.41B.

Does DXCM pay a dividend?

DexCom, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does DXCM carry?

DexCom, Inc. has a debt-to-equity ratio of 0.53. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is DXCM's profit margin?

DexCom, Inc. reports a net profit margin of 20.12% — the share of revenue left after every cost, including tax and interest.

What sector is DXCM in?

DexCom, Inc. is classified under Healthcare, in the Medical - Devices industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is DXCM listed on?

DexCom, Inc. trades on NASDAQ under the ticker DXCM.

What is DXCM's 52-week range?

Over the last year DexCom, Inc. has traded between $54.11 and $92.59.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens DXCM currently matches

On the figures above, DexCom, Inc. passes the filters for 11 of our ready-made screens, among them High ROE Stocks, Quality Stocks, High Profit Margin Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

High ROE StocksQuality StocksHigh Profit Margin StocksHigh ROA StocksCompanies With Highest ROELarge Cap StocksHealthcare Stocks To BuyHigh ROCE StocksStocks Under $100High ROE Stocks Under $100Debt to Equity Below 1 Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.